Abstract
Parkinson’s Disease is characterised by progressive loss of brain dopamine, which is usually replaced using L-dopa, however drug effectiveness is eventually limited by motor side-effects. The Reynolds’ laboratory has developed a drug-delivery system for reducing side-effects, that activates dopamine receptors via short pulses of dopamine agonist to target areas; however, the optimal doses of dopamine agonist pulses are unknown. We, therefore, sought to identify the dose of a D1-like and D2-like receptor agonist, SKF 82958 and ropinirole, respectively, required to initiate motor behaviour in a unilateral sheep model of parkinsonism